Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Renal Cell 3Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms by Site 1Neoplasm, Residual 1Lung Diseases 1Leukemia 1Kidney Neoplasms 1Gastro Intestinal Stromal Tumor 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1

Interventions

Imatinib Mesylate 13bosutinib 3Vincristine 3Dexamethasone 3Dasatinib 3Cyclophosphamide 3nilotinib 2fludarabine phosphate 2fludarabine 2Methotrexate 2Daunorubicin 2Cytarabine 2Azacitidine 2Acetaminophen 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2venetoclax 1thymoglobulin 1peginterferon alfa-2a 1flumatinib 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Prednisone 1Prednisolone 1Mycophenolic Acid 1Mitoxantrone 1Mercaptopurine 1Melphalan 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Philadelphia Chromosome × Tyrosine Kinase Inhibitors × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡